Innovation is a cornerstone of our commitment to advancing dermatology – and has been since the creation of Galderma in 1981. Today, we reaffirm this commitment with a clear, concerted focus on developing innovative technologies, products and services to protect, treat and enhance the skin.
Our best-in-class R&D pipeline features ambitious, differentiated projects that target strategic therapeutic areas across Aesthetics, Consumer Care and Prescription Medicine.
In addition to our in-house resources and capabilities, we are a dermatologic partner of choice for academic and industrial research collaboration around the world. Collaborations enable access to complementary perspectives, different areas of expertise, emerging technologies and disruptive concepts. They extend our ability to serve the needs of healthcare professionals and patients, helping to advance global health.
CURRENT PROJECTS INCLUDE:
A first-in-class investigational monoclonal antibody that blocks signaling of IL-31, a cytokine that is not only acting on pruritus but also plays a key role in skin inflammation in atopic dermatitis and prurigo nodularis, two skin conditions associated with high burden of disease.
A proprietary novel, ready-to-use, liquid formulation of investigational botulinum toxin, for the treatment of glabellar lines and lateral canthal lines.
CETAPHIL AND DIFFERIN PORTFOLIO EXPANSION
Continuously developing new products to further extend the Cetaphil and Differin range and meet the needs of specific skin conditions.